| PRM Stock | | | CAD 14.49 0.46 3.28% |
Comparative analysis suggests Income Tax Expense is positioned within a deteriorating regime. Statistical modeling of Big Pharma Income Tax Expense during 2010 to 2026 produced a r-squared of
0.42 . and median of
-2,689,642 .
View All Fundamentals Income Tax Expense | First Reported 2017-12-31 | Previous Quarter -223.8 K | Current Value -447.6 K | Quarterly Volatility 790.2 K |
Use this view alongside
Big Pharma Technical models for added context. It helps organize financial context for review. Use
Big Pharma Correlation to compare Big Pharma against competitors. The view supports competitor context.
Evaluating Big Pharma's Income Tax Expense across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Big Pharma Split's fundamental strength.
Below is the plot of the Income Tax Expense of Big Pharma Split over the last few years. It is Big Pharma's Income Tax Expense historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Big Pharma's overall financial position and show how it may be relating to other accounts over time.
Big Pharma Split Corp is a closed ended equity mutual fund launched and managed by Harvest Portfolios Group Inc. Big Pharma Split Corp was formed on September 15, 2017 and is domiciled in Canada. BIG PHARMA operates under Asset Management classification in Canada and is traded on Toronto Stock Exchange. Market structure and macro sensitivity help explain how Big Pharma behaves across regimes. Price movements may be comparatively less responsive to macroeconomic volatility. Big Pharma has a market cap of 17.62 M, ROE of -15.64%.
Methodology
Unless otherwise specified, financial data for Big Pharma Split is derived from periodic company reporting (annual and quarterly where available). Asset-level metrics are computed daily by Macroaxis LLC and refreshed regularly based on asset type. Big (CA:PRM) prices are typically delayed by approximately 20 minutes from primary exchanges for listed equities. Data may be delayed depending on reporting sources and market conventions. Assumptions: We primarily rely on public filings and market reference sources, including disclosures published by U.S. Securities and Exchange Commission (SEC) via EDGAR. Data is normalized for analytical consistency across reporting formats. All analytics are generated using standardized, rules-based models designed to promote consistency and comparability across instruments. Model assumptions, reference parameters, and selected computational inputs are available in the Model Inputs section. If you have questions about our data sources or methodology, please contact Macroaxis Support.
Analyst Sources
Big Pharma Split may have analyst coverage included in Macroaxis-derived consensus inputs when available. Updates may occur throughout the day.
This content is curated and reviewed by:
Raphi Shpitalnik - Junior Member of Macroaxis Editorial Board
Pair trading with Big Pharma can help investors hedge some company-specific exposure by balancing a long view with an offsetting position. The key question is whether the second leg adds real hedge value instead of just creating a more complex version of the same risk.
Correlation matrices help investors optimize their Big Pharma tax-loss harvesting strategy by identifying the best available substitutes. The higher the correlation to Big Pharma Split, the less the portfolio's risk profile will shift during the wash-sale waiting period.
The pairwise correlation of Big Pharma measures the historical tendency for two assets to move in the same or opposite directions. High correlations between Big Pharma Split and another holding indicate concentrated risk that may amplify losses in adverse market conditions.
Use
Correlation analysis and pair trading evaluation for Big Pharma to review hedging context. The method can be applied across sectors and broader equity sets.
Financial ratios for Big Pharma help frame valuation context across profits, cash flow, and
enterprise value. They help compare Big across valuation measures and peers.